Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Apolipoprotein C-I pseudogene 1 (APOC1P1) is a long non-coding RNA pseudogene located in the apolipoprotein gene cluster at chromosome 19q13.2, between APOC1 and APOC4. APOC1P1 does not encode a protein but generates multiple lincRNA transcripts, notably lincRNA-APOC1P1-3, which is overexpressed in breast cancer and affects cell proliferation and apoptosis by binding to tubulin and altering α-tubulin acetylation. Its biological role is regulatory rather than enzymatic or receptor-based. There is evidence for a possible function in tumorigenesis, but it is not considered a classical therapeutic target or a receptor/enzyme[2][4][5].
None reported for drugs. Functional studies show that lincRNA-APOC1P1-3 promotes breast cancer by increasing α-tubulin acetylation and inhibiting apoptosis, but it is not a druggable molecule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Apolipoprotein C-I pseudogene 1 (APOC1P1).